Jacqueline E. Reilly, PhD Student (Pharmacology)
Ms. Reilly is currently investigating the role of the isoprenoid biosynthetic pathway (IBP) proteins in the advancement of prostate cancer to androgen-independent metastases.  The importance of geranylgeranylated proteins in initiating migration and invasion of metastases was first established in breast cancers.  Since, various inhibitors of the IBP, including the statin family and nitrogenous bisphosphonates, have shown promising reductions in the metastasis of numerous cancers.  However, their unwanted depletion of farnesylated proteins and cholesterol hinder their successful use as adjunctive therapies in cancer advancement.  Consequently my project investigates the use of select inhibitors of the IBP developed in collaboration with our laboratory, studying their use in both in vitro and in vivo models of prostate cancer advancement.

Ryan M. Sheehy, PhD Candidate (Pharmacology)
Mr. Sheeby is currently researching the biological effects of a group of natural products called the schweinfurthins.  These compounds are interesting in that they have potent and differential profiles in the NCI 60 cancer cell line screen, and they are predicted to have a previously unknown mechanism of cytotoxicity.

Chaoqun Zheng, PhD Candidate (Molecular & Cellular Biology)
Mr. Zheng’s research is focused on identifying the protein targets for the schweinfurthins.   He is also characterizing the interaction of scweinfurthins with select signal transduction pathways. 



Sarah Holstein, MD PhD (Pharmacology) 1998-2003.  Currently Assistant Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY.

Susan Veneziano, PhD (nee Ownby) (Pharmacology) 1998-2003.  Currently In Vitro Director, Biosciences Laboratories, Montana State University, Bozeman, MT.

Gunhee Kim, MS (Pharmacology) 2002-05.  Currently Research Assistant, University of Iowa, Iowa City, IA.

Sumaya Hamadmad, PhD (Pharmacology) 2002-06.  Currently Adjunct Faculty, Sacred Heart University, Columbus, OH.

Jose Gallardo, MS (Pharmacology) 2004-07.  Currently Assistant Research Scientist, University of Minnesota, Minneapolis, MN.

Craig Kuder, PhD (Pharmacology) 2004-09.  Currently Medical Science Liaison for Eli Lily.

Andrew Wiemer, PhD (Molecular & Cellular Biology) 2004-08.  Currently Assistant Professor, Medical Chemistry, University of Connecticut, Storrs-Mansfield, CT.

Amel Dudakovic, PhD (Pharmacology) 2006-10.  Current Postdoctoral Fellow, Mayo Clinic, Rochester, MN.

Brian Wasko, PhD (Molecular & Cellular Biology) 2006-11.  Currently Postdoctoral Fellow, University of Washington, Seattle, WA.

Megan Weivoda, PhD (Pharmacology) 2009-11.  Postdoctoral Fellow, Oxford University, Oxford, United Kingdom.  Currently a Postdoctoral Fellow, Mayo Clinic, Rochester, MN.



David Gustin, MD.  Postdoctoral Fellow 1995-97.  Assistant Professor, University of Chicago, Chicago, IL.  Now deceased.

Matthew K. Henry, PhD.  Postdoctoral Fellow 2002-03.  Currently Chair & Associate Professor, Physiology & Pharmacology, Des Moines University, Osteopathic Medical Center, Des Moines, IA.

Shannon Miller, DO.  Postdoctoral Fellow 2002-05.  Currently employed in private industry.

Jay Sidloski, DO.  Postdoctoral Fellow 2003-05.  Currently Medical Oncologist, Cincinnati, OH

Kelly Swanson, DO.  Postdoctoral Fellow 2003-05.  Currently Medical Oncologist, Hyannis, MA.